secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azitra, Inc. (AZTR)
CIK:        0001701478
Form:       8-K
Filed at:   2025-06-17T23:59:59+00:00
Accession:  0001641172-25-015342
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azitra reports Phase 1b safety data for ATR12-351 in Netherton syndrome; no severe adverse events, 50% enrolled
--------------------------------------------------------------------------------

- No severe or serious adverse events in ongoing Phase 1b trial of ATR12-351; application site reactions transient, self-resolving, observed bilaterally.
- Trial 50% enrolled; six patients dosed with ATR12-351 (engineered S. epidermidis strain delivering LEKTI protein).
- Drug candidate generally safe and well-tolerated with occasional mild to moderate local symptoms (itch, redness, burning).
- Azitra presenting at 2025 BIO International Convention on June 17, 2025 (12:00PM ET in Boston).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701478/000164117225015342/0001641172-25-015342-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701478/000164117225015342/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-015342

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer